Neurocrine Biosciences, Inc. (NBIX) Insider Sells $128,570.00 in Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 1,625 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $79.12, for a total transaction of $128,570.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded up $2.68 during trading hours on Friday, hitting $78.56. 954,500 shares of the stock traded hands, compared to its average volume of 1,110,858. Neurocrine Biosciences, Inc. has a 12-month low of $38.43 and a 12-month high of $83.84. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. The stock has a market cap of $7,130.00, a PE ratio of -35.39, a price-to-earnings-growth ratio of 70.98 and a beta of 0.35.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the prior year, the business posted ($0.43) earnings per share. equities research analysts expect that Neurocrine Biosciences, Inc. will post -1.59 earnings per share for the current fiscal year.
Several equities analysts recently commented on the stock. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 target price (up previously from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Citigroup reissued a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Barclays raised their price target on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Finally, BMO Capital Markets raised their price target on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $82.31.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.